Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J | - |
dc.contributor.author | Yung, BC | - |
dc.contributor.author | Won Jong Kim | - |
dc.contributor.author | Chen, X | - |
dc.date.available | 2018-07-18T02:08:27Z | - |
dc.date.created | 2018-03-15 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://pr.ibs.re.kr/handle/8788114/4780 | - |
dc.description.abstract | Chemotherapeutic drugs havemade significant contributions to anticancer therapy, along with other therapeutic methods including surgery and radiotherapy over the past century. However, multidrug resistance (MDR) of cancer cells has remained as a significant obstacle in the achievement of efficient chemotherapy. Recently, there has been increasing evidence for the potential function of nitric oxide (NO) to overcomeMDR. NO is an endogenous and biocompatible molecule, contrasting with other potentially toxic chemosensitizing agents that reverse MDR effects, which has raised expectations in the development of efficient therapeutics with low side effects. In particular, nanoparticle-based drug delivery systems not only facilitate the delivery of multiple therapeutic agents, but also help bypass MDR pathways, which are conducive for the efficient delivery of NO and anticancer drugs, simultaneously. Therefore, this review will discuss the mechanism of NO in overcoming MDR and recent progress of combined NO and drug delivery systems. Published by Elsevier B. V | - |
dc.description.uri | 1 | - |
dc.language | 영어 | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | Multidrug resistance (MDR) | - |
dc.subject | Nitric oxide (NO) donor | - |
dc.subject | Cancer | - |
dc.subject | Nanoparticle | - |
dc.subject | Chemosensitization | - |
dc.title | Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.identifier.wosid | 000411202400023 | - |
dc.identifier.scopusid | 2-s2.0-85009509159 | - |
dc.identifier.rimsid | 62417 | - |
dc.date.tcdate | 2018-10-01 | - |
dc.contributor.affiliatedAuthor | Won Jong Kim | - |
dc.identifier.doi | 10.1016/j.jconrel.2016.12.026 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.263, pp.223 - 230 | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 263 | - |
dc.citation.startPage | 223 | - |
dc.citation.endPage | 230 | - |
dc.date.scptcdate | 2018-10-01 | - |
dc.description.wostc | 7 | - |
dc.description.scptc | 8 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | MESOPOROUS SILICA NANOPARTICLES | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANCE | - |
dc.subject.keywordPlus | ANTICANCER DRUGS | - |
dc.subject.keywordPlus | CO-DELIVERY | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | THERAPEUTIC APPLICATIONS | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | Multidrug resistance (MDR) | - |
dc.subject.keywordAuthor | Nitric oxide (NO) donor | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Nanoparticle | - |
dc.subject.keywordAuthor | Chemosensitization | - |